5 completed, 3 active not recruiting, 3 recruiting, 2 withdrawn. 11 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 3, Completed 3, Recruiting 3, Withdrawn 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Diwakar Davar: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) MTP-101-C - Immune-mediated Colitis (IMC), Immune-related Dermatitis | Phase 2 | Withdrawn | Diwakar Davar | 2027-01-23 | 2026-08-14 | |
| Patient Preference for Subcutaneous vs. Intravenous Immune Therapy nivolumab, pembrolizumab - Renal Cell Carcinoma, Non Small Cell Lung Cancer | Phase 2 | Recruiting | Diwakar Davar | 880 | 2025-11-04 | 2026-04-16 |
| Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma Tebentafusp - Uveal Melanoma | Phase 2 | Recruiting | Diwakar Davar | 44 | 2025-08-18 | 2026-09-09 |
| Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma Healthy Donor Fecal Microbiota Transplantation (hdFMT), Pembrolizumab, Lenvatinib - PD-1 Refractory Advanced Melanoma | Phase 2 | Withdrawn | Diwakar Davar | 2025-03-11 | 2025-09-29 | |
| Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab - Non Small Cell Lung Cancer | Phase 2 | Recruiting | Diwakar Davar | 26 | 2025-01-08 | 2026-03-23 |
| Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma Zimberelimab, Domvanalimab - Melanoma | Phase 2 | Active not recruiting | Diwakar Davar | 8 | 2022-03-16 | 2026-03-31 |
| Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Pixatimod, Nivolumab, Cyclophosphamide (low dose) - NSCLC, Metastatic Colorectal Carcinoma | Phase 2 | Completed | Diwakar Davar | 13 | 2021-12-09 | 2026-09-08 |
| Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) Pembrolizumab Injection - Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Diwakar Davar | 30 | 2021-05-11 | 2026-10-20 |
| Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT - Melanoma | Phase 2 | Completed | Diwakar Davar | 9 | 2020-09-02 | 2026-07-02 |
| Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination) - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | Diwakar Davar | 58 | 2020-06-12 | 2026-10-20 |
| CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease CMP-001, Nivolumab - Melanoma, Lymph Node Cancer | Phase 2 | Completed | Diwakar Davar | 34 | 2018-08-08 | 2025-05-14 |
| Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI - Melanoma | Phase 1 | Completed | Diwakar Davar | 30 | 2013-05-21 | 2018-08-28 |
| Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma ipilimumab - Melanoma | Early Phase 1 | Completed | Diwakar Davar | 59 | 2009-12-01 | 2017-12-07 |
Melanoma (8) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Squamous Cell (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colitis, Ulcerative (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Recurrence (1) · Uterine Cervical Neoplasms (1) · Uveal Melanoma (1)
Nivolumab (4) · pembrolizumab (4) · Ipilimumab (2) · Cyclophosphamide (1) · PG 545 (1) · dostarlimab (1) · lenvatinib (1) · tebentafusp (1) · zimberelimab (1)
United States (12)
Diwakar J Davar, MD (1) · Diwakar M Davar, MD, PhD (1) · Diwaker Davar, MD, M.Sc (1)
PMID 36648215, PMID 26380086, PMID 29973204, PMID 30352626, PMID 36634920, PMID 37175874, PMID 39486411